[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyadic International (DYAI)

Dyadic International (DYAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,091
  • Shares Outstanding, K 36,439
  • Annual Sales, $ 3,090 K
  • Annual Income, $ -7,360 K
  • EBIT $ -7 M
  • EBITDA $ -7 M
  • 60-Month Beta 1.15
  • Price/Sales 12.03
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 270.02% (-96.48%)
  • Historical Volatility 115.09%
  • IV Percentile 20%
  • IV Rank 14.28%
  • IV High 1,199.56% on 02/12/26
  • IV Low 115.21% on 05/13/26
  • Expected Move (DTE 2) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 188
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,743
  • Open Int (30-Day) 959
  • Expected Range 1.2300 to 1.2300

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.03
  • Number of Estimates 1
  • High Estimate $-0.03
  • Low Estimate $-0.03
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7301 +75.32%
on 06/24/26
1.3400 -4.48%
on 07/14/26
+0.4841 (+60.82%)
since 06/15/26
3-Month
0.6568 +94.88%
on 06/11/26
1.3400 -4.48%
on 07/14/26
+0.4047 (+46.24%)
since 04/15/26
52-Week
0.6546 +95.54%
on 03/26/26
1.3460 -4.90%
on 10/01/25
+0.2998 (+30.59%)
since 07/15/25

Most Recent Stories

More News
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the...

DYAI : 1.2250 (+1.24%)
Dyadic Expands IP Protection and Business Development Activities in Japan

JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the...

DYAI : 1.2250 (+1.24%)
An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth VisionNew York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Applied...

DYAI : 1.2250 (+1.24%)
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) , d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused...

DYAI : 1.2250 (+1.24%)
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a biotechnology...

DYAI : 1.2250 (+1.24%)
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

JUPITER, Fla., May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “our,” or the “Company”) (NASDAQ: DYAI), d/b/a Dyadic Applied BioSolutions, a global...

DYAI : 1.2250 (+1.24%)
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated meat industry Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals...

DYAI : 1.2250 (+1.24%)
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026

JUPITER, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company...

DYAI : 1.2250 (+1.24%)
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic’s production platform, with Dyadic eligible to receive a share of profits from product sales...

DYAI : 1.2250 (+1.24%)
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices

JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing...

DYAI : 1.2250 (+1.24%)

Business Summary

Dyadic International, Inc. is a leading genomics company with the groundbreaking technology that brings nature to the marketplace. Dyadic is poised to become a global leader in proteomics through the discovery, development, and manufacturing of novel products derived from the DNA of complex living organisms...

See More

Key Turning Points

3rd Resistance Point 1.6921
2nd Resistance Point 1.5161
1st Resistance Point 1.3630
Last Price 1.2250
1st Support Level 1.0339
2nd Support Level 0.8579
3rd Support Level 0.7048

See More

52-Week High 1.3460
Last Price 1.2250
Fibonacci 61.8% 1.0819
Fibonacci 50% 1.0003
Fibonacci 38.2% 0.9187
52-Week Low 0.6546

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.